Zacks: Analysts Expect Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) to Post -$0.54 EPS

Equities research analysts expect that Aerie Pharmaceuticals, Inc. (NASDAQ:AERIGet Rating) will post earnings of ($0.54) per share for the current quarter, Zacks Investment Research reports. Five analysts have issued estimates for Aerie Pharmaceuticals’ earnings. The highest EPS estimate is ($0.44) and the lowest is ($0.61). Aerie Pharmaceuticals posted earnings per share of ($0.67) in the same quarter last year, which suggests a positive year-over-year growth rate of 19.4%. The business is expected to announce its next earnings report on Monday, January 1st.

According to Zacks, analysts expect that Aerie Pharmaceuticals will report full-year earnings of ($2.13) per share for the current year, with EPS estimates ranging from ($2.33) to ($1.92). For the next year, analysts anticipate that the business will post earnings of ($1.35) per share, with EPS estimates ranging from ($1.58) to ($1.19). Zacks’ earnings per share calculations are a mean average based on a survey of analysts that cover Aerie Pharmaceuticals.

Aerie Pharmaceuticals (NASDAQ:AERIGet Rating) last issued its earnings results on Thursday, May 5th. The company reported ($0.66) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.65) by ($0.01). During the same period in the prior year, the company posted ($0.72) earnings per share.

A number of equities analysts recently issued reports on the company. Cowen cut their target price on Aerie Pharmaceuticals from $30.00 to $25.00 in a report on Friday, February 25th. StockNews.com began coverage on Aerie Pharmaceuticals in a report on Thursday, March 31st. They issued a “hold” rating on the stock. Citigroup dropped their price objective on Aerie Pharmaceuticals from $23.00 to $13.00 in a research note on Monday, February 28th. Finally, Needham & Company LLC dropped their price objective on Aerie Pharmaceuticals from $22.00 to $14.00 and set a “buy” rating on the stock in a research note on Friday, February 25th. One analyst has rated the stock with a sell rating, two have issued a hold rating and three have assigned a buy rating to the stock. Based on data from MarketBeat, Aerie Pharmaceuticals currently has a consensus rating of “Hold” and a consensus price target of $19.52.

A number of large investors have recently modified their holdings of AERI. Renaissance Technologies LLC increased its position in shares of Aerie Pharmaceuticals by 29.6% during the 1st quarter. Renaissance Technologies LLC now owns 498,210 shares of the company’s stock valued at $4,534,000 after purchasing an additional 113,900 shares during the last quarter. Charles Schwab Investment Management Inc. increased its position in shares of Aerie Pharmaceuticals by 4.8% during the 1st quarter. Charles Schwab Investment Management Inc. now owns 340,719 shares of the company’s stock valued at $3,101,000 after purchasing an additional 15,737 shares during the last quarter. Prudential Financial Inc. purchased a new stake in shares of Aerie Pharmaceuticals during the 1st quarter valued at $358,000. Allianz Asset Management GmbH increased its position in shares of Aerie Pharmaceuticals by 41.7% during the 1st quarter. Allianz Asset Management GmbH now owns 154,205 shares of the company’s stock valued at $1,403,000 after purchasing an additional 45,380 shares during the last quarter. Finally, Sei Investments Co. increased its position in shares of Aerie Pharmaceuticals by 57.4% during the 1st quarter. Sei Investments Co. now owns 46,384 shares of the company’s stock valued at $415,000 after purchasing an additional 16,914 shares during the last quarter.

Shares of AERI traded up $0.36 during trading hours on Friday, reaching $6.81. The stock had a trading volume of 512,084 shares, compared to its average volume of 520,899. Aerie Pharmaceuticals has a 12 month low of $5.46 and a 12 month high of $19.26. The firm has a 50-day simple moving average of $8.20 and a 200 day simple moving average of $8.40. The company has a market capitalization of $331.10 million, a price-to-earnings ratio of -4.54 and a beta of 0.74.

Aerie Pharmaceuticals Company Profile (Get Rating)

Aerie Pharmaceuticals, Inc, a pharmaceutical company, focuses on the discovery, development, and commercialization of ophthalmic therapies for open-angle glaucoma, dry eye, diabetic macular edema, and wet age-related macular degeneration in the United States. Its products include Rhopressa, a once-daily eye drop to reduce elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension; and Rocklatan, a once-daily fixed-dose combination of Rhopressa and latanopros to reduce IOP to treat patients with open-angle glaucoma or ocular hypertension.

Recommended Stories

Get a free copy of the Zacks research report on Aerie Pharmaceuticals (AERI)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Aerie Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aerie Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.